Publications

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

2016/02/01

Type de publication

Articles

Auteurs

Bonnet M

Bastard M

du Cros P

Khamraev A

Kimenye K

Khurkhumal S

Hayrapetyan A

Themba D

Telnov A

Sanchez-Padilla E

Hewison C

Varaine F

Thèmes

Tuberculose

Abstract

BACKGROUND:

The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poor outcome.

OBJECTIVE:

To identify patients at risk of unfavourable outcomes who may benefit from the new drugs.

METHODS:

Retrospective cohort study of treatment outcomes involving four to five effective drugs for 15-24 months in programmes in Uzbekistan, Georgia, Armenia, Swaziland and Kenya between 2001 and 2011.